Le Lézard
Classified in: Health
Subject: SVY

Surgical Suture Market Size Worth $5.9 Billion by 2025 | CAGR: 6.5%: Grand View Research, Inc.


SAN FRANCISCO, January 21, 2019 /PRNewswire/ --

The global surgical suture market size is expected to reach at USD 5.9 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 6.5% over the forecast period. The increasing cases of complicated surgeries and awareness regarding patient safety during surgeries are expected to drive the market in the next few years.

     (Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )

Aging baby boomers and introduction of various sutures by the market players are other high impact rendering market drivers. For instance, in November 2015, the U.S. Food and Drug Administration (FDA) approved RESORBA suture range developed by Advanced Medical Solutions Group plc.

Furthermore, advantages associated with multivalent sutures over staples and adhesives in complicated surgeries are likely to propel the market growth during the forecast period. Staples cause more pain and are less precise in complicated wound closure, hence sutures are preferred over staples. This factor is anticipated to bode well for the growth of the market for surgical sutures over the forecast period.

Increasing number of surgical procedures due to the presence of a large geriatric population, government support in various countries, and favorable reimbursement scenario are likely to further drive the market in the forthcoming years.

The type segment comprises absorbable and non-absorbable sutures. Absorbable suture provides temporary support to wound till it heals, can withstand normal stress, and there is no need to remove it post-surgery as it gets absorbed in the body after a certain period. This factor is anticipated to drive the demand for this type in near future.

Browse full research report with TOC on "Surgical Sutures Market Size, Share & Trends Analysis Report By Type (Absorbable, Nonabsorbable), By Filament (Monovalent, Multivalent), By Application, By End Use, And Segment Forecasts, 2019 - 2025" at: https://www.grandviewresearch.com/industry-analysis/surgical-sutures-market

Further Key Findings From the Report Suggest: 

Connect with our analyst for specific inquiries

Browse related reports by Grand View Research: 

Grand View Research has segmented the global surgical sutures market on the basis of type, filament, application, and region: 

Explore the BI enabled intuitive market research database, Grand View Compass, by Grand View Research, Inc.

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


Contact: 

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter

SOURCE Grand View Research, Inc.


These press releases may also interest you

at 07:10
Science Corporation ("Science"), a leader in brain-computer interface ("BCI") technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA ("Pixium") of France, a...

at 07:05
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...



News published on and distributed by: